Last reviewed · How we verify
Gastrin 17
At a glance
| Generic name | Gastrin 17 |
|---|---|
| Also known as | GAST-17 |
| Sponsor | City of Hope Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes (PHASE1, PHASE2)
- Islet Cell Transplant for Type 1 Diabetes (PHASE2)
- Gastrin, Anti-helicobacter Pylori and Pepsinogen Diagnostic Accuracy Study
- Blood Tests for Gastritis and Gastric Neoplasms
- Multicenter Comparison of Thermal Ablation Versus Thyroid Lobectomy for Subcapsular Papillary Thyroid Microcarcinoma
- Measuring the Negative Predictive Value and Specificity of Serum Biomarkers in Gastric Cancer
- Gastropanel for Gastric Atrophy and Cancer Risk Assessment
- Ultrasound-Guided Axillary or Infraclavicular Nerve Block for Upper Limb Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gastrin 17 CI brief — competitive landscape report
- Gastrin 17 updates RSS · CI watch RSS
- City of Hope Medical Center portfolio CI